-
1
-
-
79953881245
-
Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: The '5E' study
-
Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. Expert Rev Pharmacoecon Outcomes Res 2011;11:205-13.
-
(2011)
Expert Rev Pharmacoecon Outcomes Res
, vol.11
, pp. 205-213
-
-
Arroyo, R.1
Vila, C.2
Clissold, S.3
-
2
-
-
4444288689
-
Prevalence and treatment of spasticity reported by multiple sclerosis patients
-
Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10:589-95.
-
(2004)
Mult Scler
, vol.10
, pp. 589-595
-
-
Rizzo, M.A.1
Hadjimichael, O.C.2
Preiningerova, J.3
-
3
-
-
84893487075
-
Overview of MS spasticity
-
Pozzilli C. Overview of MS spasticity. Eur Neurol 2014;71(Suppl 1):1-3.
-
(2014)
Eur Neurol
, vol.71
, pp. 1-3
-
-
Pozzilli, C.1
-
4
-
-
0346733218
-
Treatments for spasticity and pain in multiple sclerosis: A systematic review
-
iii ix-x
-
Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7:iii, ix-x, 1-111.
-
(2003)
Health Technol Assess
, vol.7
, pp. 1-111
-
-
Beard, S.1
Hunn, A.2
Wight, J.3
-
6
-
-
33847766180
-
Sativex spasticity in MSSG. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
-
Collin C, Davies P, Mutiboko IK, et al, Sativex spasticity in MSSG. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6.
-
(2007)
Eur J Neurol
, vol.14
, pp. 290-296
-
-
Collin, C.1
Davies, P.2
Mutiboko, I.K.3
-
7
-
-
84937953069
-
Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis
-
Meuth SG, Vila C, Dechant KL. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother 2015;15:909-18.
-
(2015)
Expert Rev Neurother
, vol.15
, pp. 909-918
-
-
Meuth, S.G.1
Vila, C.2
Dechant, K.L.3
-
8
-
-
33749427038
-
Combined cannabinoid therapy via an oromucosal spray
-
Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006;42:495-503.
-
(2006)
Drugs Today (Barc
, vol.42
, pp. 495-503
-
-
Perez, J.1
-
9
-
-
4344582253
-
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
-
Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41.
-
(2004)
Mult Scler
, vol.10
, pp. 434-441
-
-
Wade, D.T.1
Makela, P.2
Robson, P.3
-
10
-
-
33745025055
-
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
-
Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45.
-
(2006)
Mult Scler
, vol.12
, pp. 639-645
-
-
Wade, D.T.1
Makela, P.M.2
House, H.3
-
11
-
-
77952835462
-
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
-
Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9.
-
(2010)
Neurol Res
, vol.32
, pp. 451-459
-
-
Collin, C.1
Ehler, E.2
Waberzinek, G.3
-
12
-
-
79953822342
-
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols∗ (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
-
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols∗ (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31.
-
(2011)
Eur J Neurol
, vol.18
, pp. 1122-1131
-
-
Novotna, A.1
Mares, J.2
Ratcliffe, S.3
-
13
-
-
84910039391
-
Advances in the management of MS spasticity: Recent observational studies
-
Fernández O. Advances in the management of MS spasticity: recent observational studies. Eur Neurol 2014;72(Suppl 1):12-14.
-
(2014)
Eur Neurol
, vol.72
, pp. 12-14
-
-
Fernández, O.1
-
14
-
-
84977776225
-
An observational post-approval registry study of patients prescribed Sativex ®. Results from clinical practice. [Poster 1041]
-
Eltayb A, Etges T, Wright S. An observational post-approval registry study of patients prescribed Sativex ®. Results from clinical practice. [Poster 1041]. Mult Scler 2013;19(Suppl 1):74.
-
(2013)
Mult Scler
, vol.19
, pp. 74
-
-
Eltayb, A.1
Etges, T.2
Wright, S.3
-
15
-
-
84900428298
-
Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity
-
Koehler J, Feneberg W, Meier M, et al. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 2014;124:652-6.
-
(2014)
Int J Neurosci
, vol.124
, pp. 652-656
-
-
Koehler, J.1
Feneberg, W.2
Meier, M.3
-
16
-
-
84901684390
-
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity
-
Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71:271-9.
-
(2014)
Eur Neurol
, vol.71
, pp. 271-279
-
-
Flachenecker, P.1
Henze, T.2
Zettl, U.K.3
-
17
-
-
84995703921
-
Observational safety study of THC:CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity
-
Celia Oreja-Guevara BC, Manuel Ordás C, Vila C, et al. Observational safety study of THC:CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity. Clin Exp Pharmacol 2015;5:184.
-
(2015)
Clin Exp Pharmacol
, vol.5
, pp. 184
-
-
Celia Oreja-Guevara, B.C.1
Manuel Ordás, C.2
Vila, C.3
-
18
-
-
44849131341
-
Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial
-
Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30:974-85.
-
(2008)
Clin Ther
, vol.30
, pp. 974-985
-
-
Farrar, J.T.1
Troxel, A.B.2
Stott, C.3
-
19
-
-
84902301875
-
Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice
-
Flachenecker P, Henze T, Zettl UK. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 2014;72:95-102.
-
(2014)
Eur Neurol
, vol.72
, pp. 95-102
-
-
Flachenecker, P.1
Henze, T.2
Zettl, U.K.3
-
20
-
-
84957838189
-
Efficacy and safety of nabiximols (Sativex) on multiple sclerosis spasticity in a real-life Italian monocentric study
-
Ferrè L, Nuara A, Pavan G, et al. Efficacy and safety of nabiximols (Sativex) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci 2016;37:235-42.
-
(2016)
Neurol Sci
, vol.37
, pp. 235-242
-
-
Ferrè, L.1
Nuara, A.2
Pavan, G.3
-
21
-
-
84956795053
-
Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis
-
Leocani L, Nuara A, Houdayer E, et al. Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol 2015;262: 2520-7.
-
(2015)
J Neurol
, vol.262
, pp. 2520-2527
-
-
Leocani, L.1
Nuara, A.2
Houdayer, E.3
|